4-anilinoquinazolines with Lavendustin A subunit as inhibitors of epidermal growth factor receptor tyrosine kinase:: syntheses, chemical and pharmacological properties

被引:25
作者
Albuschat, R
Löwe, W
Weber, M
Luger, P
Jendrossek, V
机构
[1] Free Univ Berlin, Inst Pharm, D-14195 Berlin, Germany
[2] Free Univ Berlin, Inst Crystallog, D-14195 Berlin, Germany
[3] Univ Tubingen, Dept Radiat Oncol, D-72076 Tubingen, Germany
关键词
4-anilinoquinazolines; salicylanilides; quinones; inclusion of solvents; EGFR tyrosine kinase inhibitory activity; antiproliferative effects;
D O I
10.1016/j.ejmech.2004.03.010
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
4-Anilinoquinazoline derivatives are widely investigated due to their potent epidermal growth factor receptor (EGFR) tyrosine kinase inhibitory activity. Two 4-anilinoquinazolines with Lavendustin A subunit (10a,b) were synthesized and examined for their EGFR tyrosine kinase inhibitory activity as well as their antiproliferative properties on variant human cancer cell lines. Both compounds maintained their EGFR tyrosine kinase inhibitory activity at the 10-7 M level and led to significant growth inhibition in certain leukemia, non-small cell lung cancer (NSCLC). ovarian cancer. renal cancer and breast cancer cell lines with GI(50) values at the 10-6 M level. There could not be observed any notable difference between 10a and lob regarding to their antiproliferative activity. Interestingly, we observed the high tendency of 10a and 10b to include certain solvents. e.g. water. DMF, DMSO, which may be due to the remarkable number of hydrogen accepting/donating groups in 10a and b. An X-ray analysis of 10a including water and DMF illustrates a possible hydrogen bond pattern and could serve as information for preferred receptor (e.g. EGFR tyrosine kinase) binding sites. Finally, we aimed for irreversible EGFR tyrosine kinase inhibitors. The p-quinone derivatives 11a and 11b, which contain a Michael acceptor position according to the irreversible inhibitor CI-1033. Could be derived from the p-hydroquinone derivatives 10a or 10b, respectively, by oxidation. However, due to their instability 11a and 11b could not be obtained in a pure form. (C) 2004 Elsevier SAS. All rights reserved.
引用
收藏
页码:1001 / 1011
页数:11
相关论文
共 38 条
[11]   CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins [J].
Carroll, M ;
OhnoJones, S ;
Tamura, S ;
Buchdunger, E ;
Zimmermann, J ;
Lydon, NB ;
Gilliland, DG ;
Druker, BJ .
BLOOD, 1997, 90 (12) :4947-4952
[12]  
Ciardiello F, 2000, CLIN CANCER RES, V6, P2053
[13]   Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor [J].
Fry, DW ;
Bridges, AJ ;
Denny, WA ;
Doherty, A ;
Greis, KD ;
Hicks, JL ;
Hook, KE ;
Keller, PR ;
Leopold, WR ;
Loo, JA ;
McNamara, DJ ;
Nelson, JM ;
Sherwood, V ;
Smaill, JB ;
Trumpp-Kallmeyer, S ;
Dobrusin, EM .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (20) :12022-12027
[14]  
GEISSLER JF, 1990, J BIOL CHEM, V265, P22255
[15]  
GLIVEC NM, 2001, NOVARTIS PHARM
[16]  
GREVER MR, 1992, SEMIN ONCOL, V19, P622
[17]  
GREVER MR, 1995, LIFE SCI, V57, P131
[18]   A DIAZINE HETEROCYCLE REPLACES A 6-MEMBERED HYDROGEN-BONDED ARRAY IN THE ACTIVE-SITE OF SCYTALONE DEHYDRATASE [J].
HODGE, CN ;
PIERCE, J .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1993, 3 (08) :1605-1608
[19]  
HONG WK, 2000, ONCOL BIOTHER, V1, P2
[20]  
Jendrossek V, 1999, INT J ONCOL, V14, P15